ReviewBlood2011
β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism.
Review in Blood, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
117 citing papers in PubMed, 1 synthesis or guideline pooled it, 196 citations in OpenAlex.
- Splenectomy for people with thalassaemia major or intermedia.The Cochrane database of systematic reviews · 2019Pooled it
- A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers.American journal of hematology · 2014Trial
- Resveratrol accelerates erythroid maturation by activation of FoxO3 and ameliorates anemia in beta-thalassemic mice.Haematologica · 2014Trial
- Luspatercept Induces Significant Improvement in Anemia in Dominant Thalassemia Secondary to Heterozygous STEAP3 and Beta-Thalassemia Trait.American journal of hematology · 2026Article
- Age-Related Patterns of Organ-Specific Iron Distribution in Non-Transfusion-Dependent Thalassemia: A Multicenter MRI Study.Journal of clinical medicine · 2026Article
- Article
- Evaluation of Salivary and Serum BAFF and TWEAK Levels in Patients with Thalassemia Major and Gingival Inflammation: An Observational Case-Control Study.European journal of dentistry · 2026Article
- A cell-nonautonomous heme acquisition pathway enables erythroid hemoglobinization under stress.Science (New York, N.Y.) · 2026Article
- Luspatercept: From Bench to Bedside and Beyond in the Management of Ineffective Erythropoiesis.Journal of hematology · 2026Review
- Therapeutic Potential of Deferiprone-Resveratrol Hybrid (DFP-RVT) Against Hepatic Iron Overload in β-Thalassemia Mice: A Proteomic Analysis.Biomolecules · 2026Article
- A cell-nonautonomous heme acquisition pathway enables erythroid hemoglobinization under stress.bioRxiv : the preprint server for biology · 2026Article
- SNH-119014, a novel pyruvate kinase activator, enhances ATP production and reduces oxidative stress in erythroid cells from patients with β-thalassemia major.Frontiers in pharmacology · 2026Article
- Erythropoiesis in health and disease: Distinguishing defective and ineffective erythropoiesis.HemaSphere · 2026Review
- Determinants of Multi-Organ Morbidity in Neo-Transfusion-Dependent Thalassemia: A Cross-Sectional Analysis.Journal of clinical medicine · 2025Article
- The 1357 bp deletion in β-thalassemia: molecular profiling and hematological characterization in a Guangxi cohort.Molecular biology reports · 2025Article
- Pancreatic Volume in Thalassemia: Determinants and Association with Alterations of Glucose Metabolism.Diagnostics (Basel, Switzerland) · 2025Article
- Iron-Loading Anemias.Advances in experimental medicine and biology · 2025Review
- Anti-Mullerian Hormone Evaluates Ovarian Function in Patients with Non-Transfusion-Dependent Thalassemia.Mediterranean journal of hematology and infectious diseases · 2025Article
- A glutamine metabolic switch supports erythropoiesis.Science (New York, N.Y.) · 2024Article
- Article
57 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
β-thalassemia is a disease characterized by anemia and is associated with ineffective erythropoiesis and iron dysregulation resulting in iron overload. The peptide hormone hepcidin regulates iron metabolism, and insufficient hepcidin synthesis is responsible for iron overload in minimally transfused patients with this disease. Understanding the crosstalk between erythropoiesis and iron metabolism is an area of active investigation in which patients with and models of β-thalassemia have provided significant insight. The dependence of erythropoiesis on iron presupposes that iron demand for hemoglobin synthesis is involved in the regulation of iron metabolism. Major advances have been made in understanding iron availability for erythropoiesis and its dysregulation in β-thalassemia. In this review, we describe the clinical characteristics and current therapeutic standard in β-thalassemia, explore the definition of ineffective erythropoiesis, and discuss its role in hepcidin regulation. In preclinical experiments using interventions such as transferrin, hepcidin agonists, and JAK2 inhibitors, we provide evidence of potential new treatment alternatives that elucidate mechanisms by which expanded or ineffective erythropoiesis may regulate iron supply, distribution, and utilization in diseases such as β-thalassemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.